September 7, 2022

Fortune and Great Place to Work® Name Dermavant One of the Best Small Workplaces and Best Workplaces in Biopharma in 2022

READ MORE

August 24, 2022

Dermavant to Present New Data from Phase 3 Trial Program of VTAMA® (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress

READ MORE

June 28, 2022

VTAMA® (tapinarof) cream, 1% PSOARING 3 Final Data Published in JAAD

READ MORE

May 24, 2022

FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

READ MORE

March 25, 2022

Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

READ MORE

March 11, 2022

Dermavant to Present New Data from the Phase 3 PSOARING 3 Long-Term Extension Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 American Academy of Dermatology Annual Meeting

READ MORE